Thermo Fisher Scientific Inc.(TMO) Stock Research - Grey Stern Research

Thermo Fisher Scientific Inc. (TMO) Stock Analysis

$574.59 (0.27%)

TMO Financial Performance


Use the table below to view Thermo Fisher Scientific Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $574.59 -
52 Week Low $493.30 -
52 Week High $627.88 -
Market Cap $219.8 Billion 1/10
Gross Margin 42% 7/10
Profit Margin 15% 7/10
EBITDA margin 17% 6/10
Q3 - 2024 Revenue $10.6 Billion 1/10
Q3 - 2024 Earnings $1.6 Billion 1/10
Q3 - 2024 Free Cash Flow $2.8 Billion 1/10
Trailing 4 Quarters Revenue $42.4 Billion 1/10
Trailing 4 Quarters Earnings $6.1 Billion 1/10
Quarterly Earnings Growth -5% 5/10
Annual Earnings Growth 6% 4/10
Quarterly Revenue Growth 0% 6/10
Annual Revenue Growth -1% 3/10
Cash On Hand $4.6 Billion 1/10
Short Term Debt $4.1 Billion 1/10
Long Term Debt $31.2 Billion 1/10

Thermo Fisher Scientific Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Thermo Fisher Scientific Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 35.82 4/10
PS 5.19 7/10
PB 4.49 5/10
PC 47.32 5/10
Liabilities to Equity 1.05 5/10
ROA 0.06 5/10
ROE 0.13 7/10
Current Ratio 1.95 3/10
Quick Ratio 0.13 6/10
Long Term Debt to Equity 0.64 3/10
Debt to Equity 0.72 3/10
Burn Rate 7.18 2/10
Cash to Cap 0.02 5/10
CCR 1.73 2/10
EV to EBITDA 136.26 5/10
EV to Revenue 5.91 7/10

Company Details

Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.

CEO: Mr. Marc Casper

Website: https://www.thermofisher.com

Address: 168 3rd Ave Waltham, MASSACHUSETTS

Exchange: New York Stock Exchange

Industry: Diagnostics & Research

Thermo Fisher Scientific Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Thermo Fisher Scientific Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Agilent Technologies, Inc. A $43.6 Billion
Danaher Corporation DHR $176.4 Billion
Illumina, Inc. ILMN $22.3 Billion
IDEXX Laboratories, Inc. IDXX $35.3 Billion
Waters Corporation WAT $24.2 Billion
Charles River Laboratories International, Inc. CRL $8.6 Billion
Mettler-Toledo International Inc. MTD $28.0 Billion
Invitae Corporation NVTA $5.4 Million
Guardant Health, Inc. GH $5.8 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
TMO Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 10.6 Billion $1.6 Billion
Q2 2024 $ 10.5 Billion $1.5 Billion
Q1 2024 $ 10.3 Billion $1.3 Billion
Q4 2023 $ 10.9 Billion $1.6 Billion
Q3 2023 $ 10.6 Billion $1.7 Billion
Q2 2023 $ 10.7 Billion $1.4 Billion
Q1 2023 $ 10.7 Billion $1.3 Billion
Q4 2022 $ 11.5 Billion $1.6 Billion

View All

TMO Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $4.6 Billion $100.4 Billion $35.3 Billion $49.1 Billion
Q2 2024 $7.1 Billion $98.5 Billion $35.4 Billion $47.5 Billion
Q1 2024 $5.5 Billion $97.1 Billion $35.6 Billion $45.6 Billion
Q4 2023 $8.1 Billion $98.7 Billion $34.9 Billion $46.8 Billion
Q3 2023 $6.2 Billion $97.1 Billion $35.3 Billion $45.5 Billion
Q2 2023 $3.1 Billion $94.1 Billion $34.0 Billion $43.8 Billion
Q1 2023 $3.5 Billion $94.7 Billion $35.3 Billion $42.3 Billion
Q4 2022 $8.5 Billion $97.3 Billion $34.5 Billion $44.0 Billion

View All

TMO Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $2.8 Billion $648.0 Million -$2.4 Billion
Q2 2024 $1.7 Billion -$301.0 Million $1.6 Billion
Q1 2024 $904.0 Million -$347.0 Million -$2.6 Billion
Q4 2023 $2.3 Billion -$405.0 Million $2.3 Billion
Q3 2023 $2.1 Billion -$332.0 Million $3.0 Billion
Q2 2023 $1.3 Billion -$284.0 Million -$347.0 Million
Q1 2023 $271.0 Million -$458.0 Million -$5.0 Billion
Q4 2022 $2.9 Billion -$550.0 Million $5.6 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions